Dynamic VEGF Antagonist Dosing Regimen for Angiogenic Eye Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for angiogenic eye disorders, such as age-related macular degeneration, often require frequent dosing of VEGF antagonists, which can be inconvenient and may not provide the highest level of efficacy.
Innovation Solution
A novel treatment regimen involving a VEGF antagonist, specifically Conbercept, administered at varying intervals (4-week, 8-week, and 12-week intervals) over multiple phases, including a pro re nata (PRN) basis, to optimize dosing frequency and efficacy for patients with angiogenic eye disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If VEGF antagonists are administered frequently (monthly or every 4 weeks), then therapeutic efficacy is maintained, but treatment convenience deteriorates and patient burden increases
Solution Approach 1:
The patent implements dynamic dosing by transitioning from fixed frequent dosing to flexible extended-interval dosing based on individual patient response. The regimen adapts treatment frequency (extending to 8-12 weeks or PRN) according to disease activity and patient needs, optimizing both efficacy and convenience through personalized dynamic adjustment rather than uniform frequent dosing
Solution Approach 2:
The patent changes the dosing interval parameter from traditional 4-week intervals to extended intervals of 8-12 weeks or pro re nata (PRN) basis. This parameter modification maintains therapeutic efficacy while significantly improving treatment convenience by reducing injection frequency and patient burden
2Device complexity
If VEGF antagonists are administered at standard dosing intervals, then treatment protocol simplicity is maintained, but dosing frequency cannot be optimized for individual patients
Solution Approach 1:
The patent transforms the static fixed-dosing protocol into a dynamic adaptable regimen. Clinicians can extend dosing intervals to 8-12 weeks or administer PRN based on patient response, allowing protocol flexibility and personalization while maintaining overall structural simplicity of the treatment approach
Solution Approach 2:
The patent segments the treatment protocol into distinct phases: initial monthly dosing for stabilization, followed by extended-interval dosing (8-12 weeks) or PRN administration. This segmentation allows optimization of dosing frequency at different treatment stages while maintaining protocol clarity and simplicity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This regimen demonstrates significant improvement in best-corrected visual acuity and reduction in retinal thickness, offering a more effective and potentially less frequent treatment schedule for patients with angiogenic eye disorders like neovascular AMD.
Implementation Method 1
Conbercept has a higher affinity with VEGF-A and all its isoforms by an additional fourth Ig domain of VEGFR2, which has been shown to be critical for the receptor dimerization and the enhancement of the association rate of VEGF to the receptor
Implementation Method 2
In addition, conbercept can bind to P1GF, to which biologics of anti-VEGF has no binding activity
Data Source
AI summary
The present patent application provides methods for treating patients having angiogenic eye disorder by administering a VEGF antagonist, particularly an VEGF antagonist comprising the amino acid sequence of SEQ ID NO:1 in one or more treatment phases.